Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance Journal Article


Authors: Ku, S. Y.; Rosario, S.; Wang, Y.; Mu, P.; Seshadri, M.; Goodrich, Z. W.; Goodrich, M. M.; Labbé, D. P.; Gomez, E. C.; Wang, J.; Long, H. W.; Xu, B.; Brown, M.; Loda, M.; Sawyers, C. L.; Ellis, L.; Goodrich, D. W.
Article Title: Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Abstract: Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with altered lineage marker expression, suggesting that lineage plasticity facilitates therapeutic resistance. The mechanisms underlying prostate cancer lineage plasticity are incompletely understood. Studying mouse models, we demonstrate that Rb1 loss facilitates lineage plasticity and metastasis of prostate adenocarcinoma initiated by Pten mutation. Additional loss of Trp53 causes resistance to antiandrogen therapy. Gene expression profiling indicates that mouse tumors resemble human prostate cancer neuroendocrine variants; both mouse and human tumors exhibit increased expression of epigenetic reprogramming factors such as Ezh2 and Sox2. Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy. These findings uncover genetic mutations that enable prostate cancer progression; identify mouse models for studying prostate cancer lineage plasticity; and suggest an epigenetic approach for extending clinical responses to antiandrogen therapy. © 2016 by the American Association for the Advancement of Science; all rights reserved.
Journal Title: Science
Volume: 355
Issue: 6320
ISSN: 0036-8075
Publisher: American Association for the Advancement of Science  
Date Published: 2017-01-06
Start Page: 78
End Page: 83
Language: English
DOI: 10.1126/science.aah4199
PROVIDER: scopus
PUBMED: 28059767
PMCID: PMC5367887
DOI/URL:
Notes: Article -- Export Date: 2 February 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Charles L Sawyers
    225 Sawyers
  2. Ping Mu
    8 Mu